Go Back
Altimmune, Inc. reports $20.1 million Q1 loss
By USInMinutes - May 11, 2023, 10:42 AM ET
Last Updated - Jul 18, 2023, 03:31 PM EDT
The company generated $0.21 million in quarterly revenue
Altimmune, Inc. [ALT] has reported fiscal Q1 loss of $20.10 million.
On a per-share basis, the DE based company said its diluted earnings are $0.40.
The Pharmaceutical Preparations firm posted revenue of $0.21 million in this period.
Also Read:
- Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
- Altimmune to Participate at Two Upcoming Investor Conferences
- Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for ...
- Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
- Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM ...
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News
